Collagenase Clostridium histolyticum (CCh), the first approved non-surgical treatment for Peyronie's disease (PD), was withdrawn from the European, Canadian, and Asian markets due to poor demand and lack of government reimbursement options. We sought to assess insurance approval rates and usage of CCh across Canada to understand the factors that led to its withdrawal. Data on patients prescribed CCh for PD or Dupuytren's contracture was obtained through collaboration with BioScript Solutions to assess the association of variables with insurance approval and prescription filling. We identified 3297 insurance coverage applications for Xiaflex® from April 2018 to June 2020. Of all applications for PD, 92.9% applications were approved while 7.1% were rejected. Despite the withdrawal of CCh from Canadian markets, coverage application approval rates for 2018, 2019, and 2020 were 86.5%, 90.1%, and 89.1%, respectively. Of 2921 approved applications, 88.8% prescriptions were filled. For the 376 rejected applications, 66.4% of prescriptions were filled. Overall, 90% of the cost of Xiaflex® was covered in Canada among those with extended health benefits, with an out-of-pocket expense of $210.4. Insurance coverage requests for Xiaflex® were approved at a high rate in Canada with approved patients being very likely to proceed with therapy, despite interprovincial variation.
International journal of impotence research. 2023 Aug 25 [Epub ahead of print]
David Chung, Benjamin Shiff, Dhiraj S Bal, Thomas Southall, Ruben Blachman-Braun, Marc Grenier, Ryan Flannigan, Premal Patel
Section of Urology, Department of Surgery, University of Manitoba, Winnipeg, MB, Canada., Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada., Department of Urology, University of Miami, Miami, FL, USA., BioScript Solutions, Moncton, NB, Canada., Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada., Section of Urology, Department of Surgery, University of Manitoba, Winnipeg, MB, Canada. .